A Randomized Study of First Line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer with Immunobiomarker Signature-Driven Analysis (EA5163)
A Randomized Study of First Line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer with Immunobiomarker Signature-Driven Analysis (EA5163)
Trial Category:
Lung
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
